DOCS

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

High

56.790

Open

56.010

VWAP

56.08

Vol

86.72K

Mkt Cap

10.84B

Low

55.770

Amount

4.86M

EV/EBITDA(TTM)

41.77

Total Shares

185.43M

9.79B

EV/OCF(TTM)

41.02

P/S(TTM)

20.69

Doximity, Inc. provides a digital platform for United States (U.S) medical professionals. The Company's cloud-based platform provides tools to its members, which help them to collaborate with colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with medical news and research, and manage careers. The Company supports physicians in practice of medicine with mobile and clinical workflow tools, such as voice and video telehealth, secure messaging and digital faxing. The Company's platform offers marketing, hiring, and telehealth solutions. Its marketing solutions enable pharmaceutical and health system customers to get content, services, and peer connections to medical professionals through a variety of modules. Its hiring solutions provide digital recruiting capabilities to health systems and medical recruiting firms. Its telehealth solutions consist of software tools that include voice and video dialers, designed to connect patients with care providers.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

154.22M

+12.71%

0.343

+14.24%

143.19M

+13.04%

0.307

+9.74%

134.00M

+13.5%

0.273

+9.15%

Estimates Revision

The market is revising Upward the revenue expectations for Doximity, Inc. (DOCS) for FY2025, with the revenue forecasts being adjusted by 5.47% over the past three months. During the same period, the stock price has changed by -4.71%.

Revenue Estimates for FY2025

Revise Upward

+5.47%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+10.38%

In Past 3 Month

Stock Price

Go Down

-4.71%

In Past 3 Month

17 Analyst Rating

29.92% Upside

Wall Street analysts forecast DOCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCS is 73.00 USD with a low forecast of 53.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

10 Hold

0 Sell

Moderate Buy

29.92% Upside

Current: 56.190

Low

53.00

Averages

73.00

High

90.00

29.92% Upside

Current: 56.190

Low

53.00

Averages

73.00

High

90.00

Morgan Stanley

Ricky Goldwasser

Hold

Maintains

$71 → $60

2025-04-24

Reason

Morgan Stanley

Ricky Goldwasser

Price Target

$71 → $60

2025-04-24

Maintains

Hold

Reason

Morgan Stanley lowered the firm's price target on Doximity to $60 from $71 and keeps an Equal Weight rating on the shares. The firm's checks point to about 10% year-over-year growth in digital healthcare professionals marketing in 2025, which is notably above Doximity's comments on their February 6 earnings call of 5-7% industry growth expected in 2025, the analyst tells investors. However, while near term conditions are robust and should be supportive to guiding in line with the Street estimate, macro risks have intensified with pharma companies contending with uncertainty around tariffs and disruptions at the FDA, so the line of sight into the back half of the year is "clouded," the analyst added in a preview ahead of the company's fiscal Q4 earnings report.

Keybanc

Scott Schoenhaus

Buy

Maintains

$83 → $70

2025-04-16

Reason

Keybanc

Scott Schoenhaus

Price Target

$83 → $70

2025-04-16

Maintains

Buy

Reason

KeyBanc analyst Scott Schoenhaus lowered the firm's price target on Doximity to $70 from $83 and keeps an Overweight rating on the shares. Into Q1 earnings, the firm believes the focus for the HCIT sector will be on legislative policies, healthcare system utilization, and macro concerns on a slowing economy paired with potentially higher inflation. While valuations in HCIT land remain discounted vs. healthcare more broadly, KeyBanc thinks investors should be focused on companies that can drive meet/beats over the next 12 months. Specifically, it sees the least risk from a revenue and earnings perspective from companies that are well positioned in the more stable healthcare end markets serving the payers and large pharma.

Truist Securities

Jailendra Singh

Hold

Maintains

$65 → $58

2025-04-10

Reason

Truist Securities

Jailendra Singh

Price Target

$65 → $58

2025-04-10

Maintains

Hold

Reason

Truist lowered the firm's price target on Doximity to $58 from $65 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results in the Healthcare IT industry. The industry is typically shielded from macro uncertainty, but tariffs and concerns around an economic slowdown have created broader market uncertainty, which is never good for a high-beta highly volatile group like HCIT/Digital Health/Payviders, the analyst tells investors in a research note. Truist adds that while HCIT companies may not be directly exposed to new tariffs, several of these companies serve end markets - hospitals, pharma, etc. - which are likely to see either some direct impact on their supply chain costs or could decide to slow down on their investments.

Goldman Sachs

David Roman

Hold

Maintains

$58 → $80

2025-02-10

Reason

Goldman Sachs

David Roman

Price Target

$58 → $80

2025-02-10

Maintains

Hold

Reason

Mizuho

Steven Valiquette

Hold

Maintains

$55 → $65

2025-02-10

Reason

Mizuho

Steven Valiquette

Price Target

$55 → $65

2025-02-10

Maintains

Hold

Reason

Mizuho raised the firm's price target on Doximity to $65 from $55 and keeps a Neutral rating on the shares. The company reported its third consecutive "beat and raise" quarter as it continues to increase engagement with physicians on its app, the analyst tells investors in a research note. The firm believes Doximity's new pharma client portal, which allows clients to more easily track marketing spend virtually real-time, is another key factor in accelerating revenue growth.

Needham

Scott Berg

Strong Buy

Maintains

$65 → $82

2025-02-07

Reason

Needham

Scott Berg

Price Target

$65 → $82

2025-02-07

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Doximity Inc (DOCS.N) is 42.71, compared to its 5-year average forward P/E of 59.73. For a more detailed relative valuation and DCF analysis to assess Doximity Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

59.73

Current PE

42.71

Overvalued PE

109.07

Undervalued PE

10.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

38.88

Current EV/EBITDA

29.48

Overvalued EV/EBITDA

70.06

Undervalued EV/EBITDA

7.70

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

17.48

Current PS

17.21

Overvalued PS

27.29

Undervalued PS

7.67